Company intelligence / Profile preview

Luoxis Diagnostics

Englewood, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Completed multiple clinical trials demonstrating predictive value of oxidation-reduction potential for severity/prognosis in critical care; regulatory approval obtained in the EU (CE Mark) and Canada but not the US. RedoxSYS is used mainly for research and critical care diagnostics, providing rapid, objective data on oxidative stress and antioxidant reserves in several acute and chronic diseases. Ongoing validation partnerships with leading academic and medical institutions[3][6][7][10].

Therapeutic areas: Infectious DiseasesOtherNeurology
Modalities: DeviceDiagnostic platform
Industry: Metabolite Diagnostics

Partnerships

Eurobio (France, Switzerland)Una Health Limited (UK)THP Medical (Austria)Multiple academic centers and hospitals (e.g. CNRS, INSERM, INRA, CNEVA)[3]

Beyond the preview

Go deeper on Luoxis Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luoxis Diagnostics.

Explore the full profile